跳至主要内容
临床试验/NCT06599229
NCT06599229进行中(未招募)不适用

Myocardial Perfusion Abnormalities in Hypertrophic Cardiomyopathy

University of Virginia1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2025年1月2日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
30
试验地点
1
主要终点
Peak hyperemic perfusion

研究概览

简要总结

The purpose of this study is to investigate whether myocardial microvascular perfusion in patients with hypertrophic cardiomyopathy improved after initiation of cardiac myosin inhibitor therapy.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of hypertrophic cardiomyopathy
  • Subject being initiated on clinically-indicated cardiac myosin inhibitor therapy

排除标准

  • Pregnancy
  • Lactation
  • Allergy to ultrasound enhancing agent (lipid-stabilized) or regadenoson
  • Serious AE to regadenoson
  • Hypotension
  • Serious bradycardia not addressed by pacemaker
  • Moderate or greater reactive airways disease

研究组 & 干预措施

Patients with HCM initiated on cardiac myosin inhibitor therapy

Patients with HCM who are being initiated on cardiac myosin inhibitor therapy for clinically indicated reasons.

干预措施: myocardial contrast echo (Diagnostic Test)

结局指标

主要结局

Peak hyperemic perfusion

时间窗: 3 months

Myocardial contrast echo-derived myocardial blood flow at peak hyperemia (produced by regadenoson)

次要结局

  • Resting myocardial perfusion(3 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jonathan Lindner, MD

Professor of Medicine

University of Virginia

研究点 (1)

Loading locations...

相似试验

Perfusion Abnormalities in Hypertrophic... | 临床试验